09/20/23 7:00 AMNasdaq : ACRS conferencesAclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in aRHEA-AIneutral
09/18/23 7:00 AMNasdaq : ACRS clinical trialAclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates forRHEA-AIneutral
08/07/23 7:00 AMNasdaq : ACRS earningsAclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novelRHEA-AIneutral
06/13/23 7:01 AMNasdaq : ACRS clinical trialAclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment intoRHEA-AIneutral
06/02/23 7:00 AMNasdaq : ACRS conferencesAclaris Therapeutics to Participate in Two June Healthcare Investor ConferencesAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in twoRHEA-AIneutral
05/08/23 7:00 AMNasdaq : ACRS earningsAclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financialRHEA-AIneutral
05/02/23 7:01 AMNasdaq : ACRS earningsAclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday,RHEA-AIneutral
03/27/23 7:00 AMNasdaq : ACRS conferencesAclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in aRHEA-AIneutral
03/06/23 7:00 AMNasdaq : ACRS clinical trial Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis SuppurativaAclaris Therapeutics, Inc. (NASDAQ: ACRS), aRHEA-AInegative
02/23/23 7:00 AMNasdaq : ACRS earningsAclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateAclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2022 andRHEA-AIneutral